Business
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States for the prevention of vomiting induced by motion in adults, marking the first new prescription medicine approved for this condition in more than 40 years. An innovative direct-to-consumer order platform is now available through nereus.us.
About this update from Vanda Pharmaceuticals Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Consumers can now order NEREUS™ directly at nereus.us","length":53,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":53,"olType":false},{"type":"text","content":"WASHINGTON, May 1, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States for the prevention of vomiting induced by motion in adults, marking the first new prescription medicine approved for this condition in more than 40 years. An innovative direct-to-consumer order platform is now available through nereus.us.","length":426,"tagName":"p"},{"type":"image","alt":"Vanda Logo (PRNewsfoto/Vanda Pharmaceuticals Inc.)","displaySize":"","headline":null,"caption":"Vanda Logo (PRNewsfoto/Vanda Pharmaceuticals Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":260,"url":"https://media.zenfs.com/en/prnewswire.com/743d2f4492e0b465012535111f8b6bc6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Gg3NnHbVhI0MEomtkVbguw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ1OA--/https://media.zenfs.com/en/prnewswire.com/743d2f4492e0b465012535111f8b6bc6","width":400,"height":260}},"href":"https://mma.prnewswire.com/media/2090054/VandaLogo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Motion sickness affects an estimated 65 to 78 million Americans—roughly 25 to 30 percent of adults—during everyday travel by car, plane, or boat. For decades, patients have had no meaningful new treatment options. That changes today with NEREUS™, an oral neurokinin-1 (NK-1) receptor antagonist that offers a modern, targeted approach to a problem that has long lacked innovation.","length":380,"tagName":"p"},{"type":"text","content":""Today marks an important milestone for the tens of millions of Americans who experience motion sickness symptoms during common travel," said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of Vanda. "NEREUS™ is a selective, high-affinity antagonist of human substance P/neurokinin-1 (NK-1) receptors that can block the vomiting center of the brain. We are excited to make this innovative therapy available through both traditional pharmacy channels and our new direct-to-consumer platform at nereus.us, giving travelers, families, and anyone affect...